William H Yang

Summary

Publications

  1. doi request reprint An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension
    Marc A Riedl
    University of California San Diego School of Medicine, 8899 University Center Lane, Suite 230, San Diego, CA 92122 USA
    Clin Transl Allergy 7:36. 2017
  2. doi request reprint Insights and advances in chronic urticaria: a Canadian perspective.
    Gordon Sussman
    University of Toronto, Medicine, Toronto, ON Canada
    Allergy Asthma Clin Immunol 11:7. 2015
  3. doi request reprint Successful use of daily intravenous infusion of C1 esterase inhibitor concentrate in the treatment of a hereditary angioedema patient with ascites, hypovolemic shock, sepsis, renal and respiratory failure.
    Hoang Pham
    Faculty of Medicine, University of Ottawa, Ottawa, Ontario Canada
    Allergy Asthma Clin Immunol 10:62. 2014
  4. doi request reprint Canadian hereditary angioedema guideline.
    Stephen Betschel
    University of Toronto, Toronto, Ontario Canada
    Allergy Asthma Clin Immunol 10:50. 2014
  5. doi request reprint The prophylactic use of C1 inhibitor in hereditary angioedema patients undergoing invasive surgical procedures: a retrospective study.
    Genevi ve Gavigan
    Division of Dermatology, Department of Medicine, University of Ottawa, Ottawa, Canada Division of Dermatology, Department of Medicine, Ottawa Hospital Research Institute, Ottawa, Canada
    Allergy Asthma Clin Immunol 10:17. 2014
  6. doi request reprint Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial
    William H Yang
    Allergy and Asthma Research Center and University of Ottawa Medical School, Ottawa, ON, Canada
    Vaccine 31:4389-97. 2013
  7. doi request reprint Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study
    William H Yang
    Allergy and Asthma Research Centre, Ottawa, Ontario, Canada
    Ann Allergy Asthma Immunol 99:555-61. 2007
  8. ncbi request reprint Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study
    Sabina Rak
    Section of Allergy, Sahlgrenska University Hospital, Goteborg, Sweden
    Qual Life Res 16:191-201. 2007

Collaborators

  • Ping Li
  • Petr Pohunek
  • J Beier
  • Sabina Rak
  • Gordon Sussman
  • Stephen Betschel
  • Marc A Riedl
  • Marco Cicardi
  • Timothy Craig
  • Gina Lacuesta
  • Amin Kanani
  • Jacques Hebert
  • Susan Waserman
  • Genevi ve Gavigan
  • Hoang Pham
  • Stephanie Santucci
  • Jennifer Schranz
  • Aleena Banerji
  • Hilary J Longhurst
  • Jonathan A Bernstein
  • Paula J Busse
  • Jovanna Baptista
  • Markus Magerl
  • Mustafa M Shennak
  • Jan Dutz
  • Spencer Horemans
  • F Estelle R Simons
  • Kenneth Kobayashi
  • Wayne Gulliver
  • Moshe Ben-Shoshan
  • Peter Vadas
  • Charles Lynde
  • Neil Shear
  • Hermenio Lima
  • Carly Barron
  • Karen Binkley
  • Hilary Longhurst
  • Bruce Ritchie
  • Jacquie Badiou
  • Henriette Farkas
  • Rachel Harrison
  • Emel Aygören-Pürsün
  • Konrad Bork
  • Karen Dallas
  • Kelly Lang-Robertson
  • Tom Bowen
  • Beno t Laramée
  • Sean Mace
  • Henrik Boysen
  • Bill Yang
  • John Dean
  • Paul Keith
  • Donald Stark
  • Teresa Caballero
  • Rozita Borici-Mazi
  • Bruce Zuraw
  • Man Chiu Poon
  • Eric Leith
  • Jacob Karsh
  • Jonathan Bernstein
  • Bill Moote
  • Christine McCusker

Detail Information

Publications8

  1. doi request reprint An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension
    Marc A Riedl
    University of California San Diego School of Medicine, 8899 University Center Lane, Suite 230, San Diego, CA 92122 USA
    Clin Transl Allergy 7:36. 2017
    ..A Phase 1b study supported its efficacy in preventing attacks. A Phase 3, randomized, double-blind, placebo-controlled, parallel-arm study has been completed and an open-label extension is currently ongoing...
  2. doi request reprint Insights and advances in chronic urticaria: a Canadian perspective.
    Gordon Sussman
    University of Toronto, Medicine, Toronto, ON Canada
    Allergy Asthma Clin Immunol 11:7. 2015
    ..For urticaria refractory to H1-antihistamines, omalizumab treatment has emerged as an effective, safe option...
  3. doi request reprint Successful use of daily intravenous infusion of C1 esterase inhibitor concentrate in the treatment of a hereditary angioedema patient with ascites, hypovolemic shock, sepsis, renal and respiratory failure.
    Hoang Pham
    Faculty of Medicine, University of Ottawa, Ottawa, Ontario Canada
    Allergy Asthma Clin Immunol 10:62. 2014
    ..Therefore, pdC1-INH concentrate may be an effective treatment option to consider for critically-ill patients with HAE...
  4. doi request reprint Canadian hereditary angioedema guideline.
    Stephen Betschel
    University of Toronto, Toronto, Ontario Canada
    Allergy Asthma Clin Immunol 10:50. 2014
    ..Hospital administrators, insurers and policy makers may also find this guideline helpful...
  5. doi request reprint The prophylactic use of C1 inhibitor in hereditary angioedema patients undergoing invasive surgical procedures: a retrospective study.
    Genevi ve Gavigan
    Division of Dermatology, Department of Medicine, University of Ottawa, Ottawa, Canada Division of Dermatology, Department of Medicine, Ottawa Hospital Research Institute, Ottawa, Canada
    Allergy Asthma Clin Immunol 10:17. 2014
    ....
  6. doi request reprint Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial
    William H Yang
    Allergy and Asthma Research Center and University of Ottawa Medical School, Ottawa, ON, Canada
    Vaccine 31:4389-97. 2013
    ..This study (NCT00979602) evaluated the immunogenicity and relative protective efficacy of one dose of influenza A(H1N1)pdm09 vaccine with or without AS03 (an α-tocopherol oil-in-water emulsion based Adjuvant System)...
  7. doi request reprint Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study
    William H Yang
    Allergy and Asthma Research Centre, Ottawa, Ontario, Canada
    Ann Allergy Asthma Immunol 99:555-61. 2007
    ..Indacaterol is a novel, inhaled, once-daily beta2-agonist...
  8. ncbi request reprint Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study
    Sabina Rak
    Section of Allergy, Sahlgrenska University Hospital, Goteborg, Sweden
    Qual Life Res 16:191-201. 2007
    ..These data show that sublingual immunotherapy with grass allergen tablets improves QOL in allergic rhinoconjunctivitis, reduces symptoms, and that this effect is greater than rescue antihistamine alone...